Steroid News and Research

RSS

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Study: LABA can be effective step-up treatment for children whose asthma is not well controlled

For children whose asthma is not well controlled and on low doses of inhaled corticosteroids, a long-acting beta-agonist (LABA) may be the most effective of three possible step-up treatments. National Jewish clinician-scientists Stanley Szefler, Joseph Spahn, Ronina Covar Gary Larsen and Lynn Taussig, and colleagues in the NIH-funded Childhood Asthma Research and Education Network published their findings March 2, 2010, online in the New England Journal of Medicine.

3 Mar 2010

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM").

3 Mar 2010

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Lux Biosciences, Inc. today announced that the European Medicines Agency has accepted the filing of the company’s Marketing Authorization Application (MAA) for the company’s lead product, Luveniq™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

3 Mar 2010

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.

1 Mar 2010

Unexplained, sudden anemia: Brown recluse spider bite

As spring approaches and people return to outdoor activities, caution should be taken in areas of the country that are home to Loxosceles reclusa, also called the brown recluse spider. A new study from St. Jude Children's Research Hospital found that when patients present with sudden anemia, but the cause is elusive, the brown recluse spider should be part of the differential diagnosis, at least in parts of the nation where the spider is regularly found.

27 Feb 2010

New dietary supplement blocks triggering mechanism causing breast cell mutations

Every 13 minutes a woman loses her battle with breast cancer and in 2009 alone more than 27,000 men died from prostate cancer. These powerful statistics continue to fuel research and new developments. With tens of millions of dollars in financial support from the National Cancer Institute and the U.S. Department of Defense, scientists have identified when estrogen metabolism is out of balance it can start the process leading to breast cell mutations.

26 Feb 2010

Dangers of steroid abuse: Steroids.com gone live

Effective today, Steroids.com has gone live under new ownership with the primary goal to educate youths about the dangers of steroid abuse. Backed by the legal team at Womack & Associates of Houston, Texas, Steroids.com aims to become the de-facto informational website related to all things steroids.

25 Feb 2010

Study demonstrates Prochymal treamtent is safe for cardiac patients

“Patients receiving Prochymal did better than those receiving only standard-of-care,” said Dr. Hare, lead author of the JACC publication.

25 Feb 2010

Inverseon comments on LABAs and INV102CR drugs

Inverseon, Inc. (http://www.inverseon.com) comments on Long Acting Beta-Agonists (LABAs) and INV102CR.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

Observational study on mild demonstrates acute safety of procedure in treatment of LSS

Medical device company Vertos Medical Inc. has reported that an observational study on mild, published in the January/February 2010 issue of the peer-reviewed journal Pain Physician, has demonstrated the acute safety of the procedure in the treatment of lumbar spinal stenosis (LSS).

24 Feb 2010

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Prochymal achieves response rate of 63% when used as rescue therapy in children suffering from GvHD

Osiris Therapeutics, Inc. today reported that a new study shows Prochymal achieved an overall response rate of 63% when used as a rescue therapy in children suffering from severe treatment resistant graft vs. host disease (GvHD).

24 Feb 2010

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Osiris Therapeutics, Inc. today announced that results from the Phase III trial evaluating Prochymal for the treatment of steroid-refractory acute graft vs. host disease (GvHD) will be presented by Paul Martin, M.D., of the Fred Hutchinson Cancer Research Center and Paul Szabolcs, M.D., of Duke University Medical Center at the 2010 BMT Tandem Meeting. The meeting is being held February 24-28 in Orlando, Florida.

24 Feb 2010

Passage of DSSA will restrict Americans’ access to nutritional supplements, says Hotze Enterprises

On Feb. 4, Senators John McCain and Byron Dorgan introduced the Dietary Supplement Safety Act of 2010 (DSSA), that if passed, will restrict Americans’ access to nutritional supplements. Hotze Enterprises, a world leader in the alternative health care industry, is strongly opposed to this legislation being passed, and encourages consumers to take action.

19 Feb 2010

Steroids and weight loss products can accelerate hair loss, says hair loss expert

In a study due to be released next month, the world's leading hair transplant and hair loss expert Dr. Larry Shapiro will show that men and women have been losing their hair from using popular weight loss and work out products that contain whey protein isolate- and it's not just their genes that are to blame.

19 Feb 2010

Acute sinus infections always begin as cold

Have a cold that just won't go away or is getting worse? Chances are your cold has developed into a sinus infection - a common problem this time of year, says Alan Wild, M.D., assistant professor of otolaryngology at Saint Louis University School of Medicine.

18 Feb 2010

Ibuprofen may reduce risk of Parkinson's disease, says study

New research shows people who regularly take ibuprofen may reduce their risk of developing Parkinson's disease, according to a study released today that will be presented at the American Academy of Neurology's 62nd Annual Meeting in Toronto April 10 to April 17, 2010.

18 Feb 2010

New research units established for Japanese-German research collaboration

With its ten new Research Units, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is intensifying interdisciplinary and multiple-location collaboration among researchers pursuing specific scientific questions and new avenues of research.

17 Feb 2010

Steroid News and Research

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Study: LABA can be effective step-up treatment for children whose asthma is not well controlled

Shionogi, QuatRx Pharmaceuticals enter into worldwide license agreement to develop and market ospemifene

EMA accepts the filing of Lux Biosciences' MAA for Luveniq

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

Unexplained, sudden anemia: Brown recluse spider bite

New dietary supplement blocks triggering mechanism causing breast cell mutations

Dangers of steroid abuse: Steroids.com gone live

Study demonstrates Prochymal treamtent is safe for cardiac patients

Inverseon comments on LABAs and INV102CR drugs

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Observational study on mild demonstrates acute safety of procedure in treatment of LSS

Osiris Therapeutics' net income for fourth-quarter 2009 increases to $15.7M

Prochymal achieves response rate of 63% when used as rescue therapy in children suffering from GvHD

Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting

Passage of DSSA will restrict Americans’ access to nutritional supplements, says Hotze Enterprises

Steroids and weight loss products can accelerate hair loss, says hair loss expert

Acute sinus infections always begin as cold

Ibuprofen may reduce risk of Parkinson's disease, says study

New research units established for Japanese-German research collaboration

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News